Browse CXCL5

Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF00048 Small cytokines (intecrine/chemokine)
Function

Involved in neutrophil activation. In vitro, ENA-78(8-78) and ENA-78(9-78) show a threefold higher chemotactic activity for neutrophil granulocytes.

> Gene Ontology
 
Biological Process GO:0002237 response to molecule of bacterial origin
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002446 neutrophil mediated immunity
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0040017 positive regulation of locomotion
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0060326 cell chemotaxis
GO:0070098 chemokine-mediated signaling pathway
GO:2000147 positive regulation of cell motility
Molecular Function GO:0001664 G-protein coupled receptor binding
GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0008009 chemokine activity
GO:0042379 chemokine receptor binding
GO:0045236 CXCR chemokine receptor binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04062 Chemokine signaling pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-380108: Chemokine receptors bind chemokines
R-HSA-373076: Class A/1 (Rhodopsin-like receptors)
R-HSA-418594: G alpha (i) signalling events
R-HSA-388396: GPCR downstream signaling
R-HSA-500792: GPCR ligand binding
R-HSA-375276: Peptide ligand-binding receptors
R-HSA-162582: Signal Transduction
R-HSA-372790: Signaling by GPCR
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between CXCL5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between CXCL5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
24525743Hepatocellular carcinomaInhibit immunity (T cell function)Mechanistic investigations showed that IL-17A induced CXCL5 production by tumor cells to enhance the infiltration of myeloid-derived suppressor cells (MDSC) to tumor sites in a CXCL5/CXCR2-dependent manner.
29036438Gastric CarcinomaInhibit immunity (T cell function)We generated a xenograft mouse model and used SEW-2871, a S1P1 specific agonist to activate S1P1 signalling. SEW-2871 promoted tumor growth in our mouse model, and induced a higher level of MDSC and a reduced level of CD8+CD69+ T cells within tumor. Additionally, SEW-2871 enhanced expression of several MDSC recruitment-associated chemokines (CXCL12, CXCL5 and CCL2) in tumor cells. These chemokines facilitated MDSC migration by interaction with CCR2, CXCR2 and CXCR4. S1P1 signalling promoted gastric cancer by enhancing chemokine expression in tumor cells and recruiting MDSC to tumor microenvironment, which impaired anti-tumoral function of TILs.
23737434Breast CarcinomaInhibit immunity (T cell function)Finally, we found that CXCL5/CXCR2 axis facilitated MDSC migration and that anti-GM-CSF antibodies neutralized CXCL5-induced accumulation of MDSCs. Taken together, our data suggest that KLF4 modulates maintenance of MDSCs in bone marrow by inducing GM-CSF production via CXCL5 and regulates recruitment of MDSCs into the primary tumors through the CXCL5/CXCR2 axis, both of which contribute to KLF4-mediated mammary tumor development.
27737879Pancreatic Ductal AdenocarcinomaInhibit immunity (T cell function)CXCL5 was the most prominently expressed CXCR2 ligand in human PDA, and its expression was higher in PDA than in any other common tumor represented in The Cancer Genome Atlas. Cxcl5 expression was associated with mutant Kras expression and regulated by NF-κB activation.
24346967Lung CarcinomaInhibit immunity; Resistant to immunotherapyCXCL5 not only potentiated the classical EGFR pathway and the AKT and ERK/RSK1/2 signaling pathways but also increased the phosphorylation of heat shock protein 27 (HSP27), which was slightly increased in A549 cells treated with either HB-EGF or CXCL5 only. Phosphorylated HSP27 stabilized sustained AKT activity by direct interaction, leading to enhanced tumor spheroid formation. In mice, CXCL5 antibody synergistically enhances the efficiency of the tyrosine kinase inhibitor, gefitinib, without increasing its toxicity.
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of CXCL5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of CXCL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.0020.189
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2750.301
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.8050.446
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-2.5180.00926
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-3.610.00552
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.1140.522
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.10.905
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.40.237
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.4450.253
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.6520.04
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.4240.205
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1280.745
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of CXCL5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CXCL5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CXCL5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CXCL5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CXCL5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of CXCL5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between CXCL5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolCXCL5
Namechemokine (C-X-C motif) ligand 5
Aliases ENA-78; SCYB5; small inducible cytokine subfamily B (Cys-X-Cys), member 5 (epithelial-derived neutrophil-act ......
Chromosomal Location4q13.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting CXCL5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.